Immunotherapy in patients with small cell lung cancer, a chance for a longer and quality life - case report

Abstract

Immunotherapy is the new hope for longer survival for patients with small cell lung cancer. So far, it has only been given in trials, but 2022 has become a breakthrough year.

In comprehensive cancer centers, these patients have a chance of receiving reimbursed treatment with durvalumab (with chemotherapy). Our case report focuses on the appropriateness of patient selection for this treatment, as long-term experience outside clinical trials is still limited.